idelalisib: Clinical Trials

21 trials of idelalisib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 10 terminated, 1 withdrawn. 21 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 121Completed 10, Terminated 10, Withdrawn 1
Phase 24Terminated 3, Completed 1

Follow idelalisib: new trials by email Literature Review of idelalisib trials Research Report on idelalisib

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1TerminatedOHSU Knight Cancer Institute22020-04-012024-03-04
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
Idelalisib, Rituximab, Ifosfamide - Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma
Phase 1WithdrawnGilead Sciences2019-06-012018-12-11
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Idelalisib 100 MG, Placebo Oral Tablet - B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia
Phase 1TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins162018-07-312024-03-12
REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia
Idelalisib - Acute Lymphoblastic Leukemia
Phase 1 / Phase 2TerminatedPETHEMA Foundation62018-07-012021-09-05
Pembrolizumab + Idelalisib for Lung Cancer Study
Pembrolizumab, Idelalisib - Non Small Cell Lung Cancer, Metastasis
Phase 1 / Phase 2TerminatedAsha Nayak42017-09-262024-02-28
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
ACY-1215, Ibrutinib, Idelalisib - Recurrent Chronic Lymphoid Leukemia
Phase 1CompletedDana-Farber Cancer Institute32016-05-012026-11-12
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 1CompletedOHSU Knight Cancer Institute72016-01-132020-05-26
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
Idelalisib, BI 836826 - Chronic Lymphocytic Leukemia (CLL)
Phase 1TerminatedGilead Sciences22015-12-292020-11-25
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
BCL201, Idelalisib - Follicular Lymphoma, Mantle Cell Lymphoma
Phase 1CompletedNovartis Pharmaceuticals202015-11-162020-02-24
Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
Idelalisib, Nab-paclitaxel, mFOLFOX6 - Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
Phase 1TerminatedGilead Sciences162015-07-302021-04-02
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Tirabrutinib, Idelalisib, Entospletinib - B-cell Malignancies
Phase 1TerminatedGilead Sciences2032015-06-162025-06-17
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
Idelalisib, Ruxolitinib - Myelofibrosis
Phase 1TerminatedGilead Sciences102015-06-052020-09-16
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
Idelalisib - Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma
Phase 1CompletedGilead Sciences62014-10-012021-03-19
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
lenalidomide, idelalisib - Relapsed/Refractory Mantle Cell Lymphoma
Phase 1CompletedAlliance for Clinical Trials in Oncology1062013-10-172026-06-16
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
idelalisib, lenalidomide - Recurrent Follicular Lymphoma
Phase 1CompletedAlliance for Clinical Trials in Oncology82013-08-022026-06-16
Phase 1b Safety and Efficacy Study of TRU-016
20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab - Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
Phase 1TerminatedAptevo Therapeutics872012-09-012021-05-20
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Idelalisib - Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2CompletedGilead Sciences182011-02-012018-11-19
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Idelalisib, Rituximab, Bendamustine - Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Phase 1CompletedGilead Sciences2412010-03-252021-03-18
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
Idelalisib - Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin
Phase 1 / Phase 2TerminatedGilead Sciences2022010-03-222019-08-28
Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
CAL-101, Placebo - Allergic Rhinitis
Phase 1CompletedGilead Sciences412009-02-012018-10-23

Showing 20 of 21. Sign in to see all of them.

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (9)  ·  Lymphoma, Follicular (5)  ·  Lymphoma, Mantle-Cell (4)  ·  Lymphoma, Non-Hodgkin (4)  ·  Leukemia, Myeloid, Acute (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Multiple Myeloma (2)  ·  Neoplasm Metastasis (2)  ·  Primary Myelofibrosis (2)  ·  Recurrence (2)  ·  Anemia (1)  ·  Blast Crisis (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)

Sponsors

Gilead Sciences (11)  ·  Alliance for Clinical Trials in Oncology (2)  ·  OHSU Knight Cancer Institute (2)  ·  Aptevo Therapeutics (1)  ·  Asha Nayak (1)  ·  Dana-Farber Cancer Institute (1)  ·  Novartis Pharmaceuticals (1)  ·  PETHEMA Foundation (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Countries

United States (17)  ·  France (3)  ·  Austria (2)  ·  Spain (2)  ·  Germany (1)  ·  Italy (1)  ·  Japan (1)  ·  Poland (1)  ·  United Kingdom (1)

Top investigators

Douglas Gladstone, MD (1)  ·  Friedrich Horak, MD (1)  ·  Jennifer B Brown, MD, PhD (1)  ·  John P. Leonard, MD (1)  ·  Lara Davis, MD (1)  ·  Scott C. Stromatt, M.D. (1)  ·  Sonali Smith, MD (1)  ·  Stephen Spurgeon (1)  ·  Zhonglin Hao, MD, PhD (1)

Results publications

PMID 21816833, PMID 24615776, PMID 24615777, PMID 24615778, PMID 28314699, PMID 29296805, PMID 31723767, PMID 26472751, PMID 26915677, PMID 28178345, PMID 32856068, PMID 39863139

NIH funding

U10CA031946 (2), 2015 (1), 2017 (1), P30CA069533 (1)